On July 26, 2022 Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, reported that it has carried out a rights issue of approximately SEK 75 million (the "Rights Issue") (Press release, Scandion Oncology, JUL 26, 2022, View Source,c3605679 [SID1234616951]). Today, on July 26, 2022, the share capital increase and updated articles of association have been registered with the Danish Business Authority (Erhvervsstyrelsen).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The last day of trading in paid subscribed shares (BTAs) is July 29, 2022. BTAs will be converted to shares on August 4, 2022. The new shares are expected to be booked into the respective custodian/VP account on August 4, 2022.

As a result of the Rights Issue and the registration of the new shares with the Danish Business Authority, the Company’s share capital has been increased by nominally DKK 629,999.9580 to a total of nominally DKK 2,991,962.4420. The number of shares and voting rights in the Company has increased by 8,571,428 shares to a total of 40,706,972 shares all with voting rights and with a nominal value of DKK 0.0735 each.

The updated articles of association of the Company are available on the Company’s website, View Source

Advisers

Redeye AB acts as financial adviser and Horten Advokatpartnerselskab (as to Danish law) and Advokatfirman Schjødt (as to Swedish law) act as legal advisers in connection with the Rights Issue. Hagberg & Aneborn Fondkommission AB acts as the issuing agent in the Rights Issue.